ScanBalt Business Partner Seach: Ivex Lab – Development of preclinical models aiding novel cancer drug efficacy studies in vivo
We look for partners and investors who are interested in cancer drug development. Our goal is to produce preclinical models with better predictive value than currently available. We focus to whole-body bioluminescence and fluorescence imaging in vivo, that enables continuous monitoring of disease progression/regression. We clone and produce lentiviral vectors expressing palettes of novel fluorescent proteins. Attached image shows pseudocoloured image of the mouse with five tumors each expressing a different fluorescent protein.
ScanBalt News
19 February 2025
Unlocking Opportunities: Latest Trends & Developments in Sweden’s Life Sciences & Health Sectors | 7 March 2025, 10:00-11:00 CET (online)
18 October 2024
Unlocking Europe's Potential in Bioproduction | 12 November 2024 | 10:30-12:00 CET (online)
10 October 2024
NOME Startup Competition 2024 | Dealine November 1st